Robert Brodsky
Feb 27, 2025, 13:40
Robert Brodsky: Haploidentical Bone Marrow Transplantation for Sickle Cell Disease
Robert Brodsky, President of American Society of Hematology and Chief of Hematology at Johns Hopkins, shared an article by Adetola A. Kassim, et al. on X:
“Out in NEJM Evidence today.
KEY TAKEAWAYS:
- Of 42 people with severe SCD who had the procedure , 95% were alive at 2 yrs, and 88% are considered cured.
- Most people with SCD are eligible, which costs a fraction of the price of gene editing/therapy.
Haploidentical Bone Marrow Transplantation for Sickle Cell Disease.
Authors: Adetola A. Kassim, et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 2, 2025, 17:18
Jun 2, 2025, 17:06
Jun 2, 2025, 15:40
Jun 2, 2025, 15:37
Jun 2, 2025, 15:20
Jun 2, 2025, 14:49
Jun 2, 2025, 13:13